A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer
Keyword(s):
Keyword(s):
2019 ◽
Vol 133
◽
pp. 145-159
◽
Keyword(s):
2010 ◽
2012 ◽
2019 ◽
Vol 11
(18)
◽
pp. 16336-16346
◽
Keyword(s):
Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues
2019 ◽
Vol 26
(2)
◽
pp. 1229-1234
◽
Keyword(s):